Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Multiple Myeloma 5Neoplasms 3Glioma 2Unspecified Childhood Solid Tumor, Protocol Specific 1Rhabdoid Tumor 1Ovarian Neoplasms 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Medulloblastoma 1Glioblastoma 1Fallopian Tube Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1Anemia 1

Interventions

Paclitaxel 81Trastuzumab 76Fulvestrant 55Cyclophosphamide 49Capecitabine 42Lapatinib 40pembrolizumab 38Docetaxel 38palbociclib 36Carboplatin 32Letrozole 28olaparib 23Doxorubicin 23Gemcitabine 21Taxes 20Everolimus 20ribociclib 19abemaciclib 19Ado-Trastuzumab Emtansine 18pertuzumab 17Radiotherapy 17Magnetic Resonance Spectroscopy 17Bevacizumab 16130-nm albumin-bound paclitaxel 16exemestane 15Vinorelbine 15Cisplatin 15veliparib 14Biopsy 14Alpelisib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Breast Neoplasms × reolysin × Clear all
NCT05519059 2023-11-22

Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer

Adlai Nortye Biopharma Co., Ltd.

Phase 1 Completed
15 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡